+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Smoking Cessation and Nicotine De-Addiction Products Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

  • ID: 4702529
  • Report
  • October 2018
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • McNeil AB
  • NJOY, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • MORE
The report on global smoking cessation and nicotine de-addiction products market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global smoking cessation and nicotine de-addiction products market to grow with a CAGR of 13.90% over the forecast period of 2018-2024. The study on smoking cessation and nicotine de-addiction products market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.

The report on smoking cessation and nicotine de-addiction products market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global smoking cessation and nicotine de-addiction products market over the period of 2016 to 2024. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global smoking cessation and nicotine de-addiction products market over the period of 2016 to 2024. Further, the Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.

Research Methodology

Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through:

1. Key Opinion Leaders associated

2. Internal and External subject matter experts

3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers

Primary research respondents typically include:

1. Executives working with leading companies in the market under review

2. Product/brand/marketing managers

3. CXO level executives

4. Regional/zonal/country managers

5. Vice President level executives.

Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

Secondary sources of the data typically include:

1. Company reports and publications

2. Government/institutional publications

3. Trade and associations journals

4. Databases such as WTO, OECD, World Bank, and among others.

5. Websites and publications by research agencies

Report Findings

1. Drivers
  • Growing Awareness about Health Problems due to Smoking
  • Government Initiatives to Spread Awareness about Ill-Effects of Smoking
2. Restraints
  • Presence of De-addiction centers and non-government organizations
3. Opportunity
  • Growing Consciousness among Cigarette Smokers
Segment Covered

The global smoking cessation and nicotine de-addiction products market is segmented on the basis of type and distribution channel.

Global Smoking Cessation and Nicotine De-addiction Products Market by Type
  • E-cigarettes
  • Drug Therapy
  • Nicotine Replacement Therapies
Global Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
  • Drug Store
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
Company Profiles
  • Takeda Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • NJOY, Inc.
  • Imperial Tobacco Company of India Limited.
  • Cipla Ltd.
  • Revolymer PLC
  • Novartis International AG
  • McNeil AB
  • GlaxoSmithKline Plc
What does this report deliver?

1. Comprehensive analysis of the global as well as regional markets of smoking cessation and nicotine de-addiction products market.

2. Complete coverage of all the segments in smoking cessation and nicotine de-addiction products market to analyze the trends, developments in the global market and forecast of market size up to 2024.

3. Comprehensive analysis of the companies operating in global smoking cessation and nicotine de-addiction products market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • McNeil AB
  • NJOY, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Smoking Cessation and Nicotine De-Addiction Products Market Highlights
2.2. Smoking Cessation and Nicotine De-Addiction Products Market Projection
2.3. Smoking Cessation and Nicotine De-Addiction Products Market Regional Highlights

3. Global Smoking Cessation and Nicotine De-Addiction Products Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Type
3.4.2. Growth Matrix Analysis by Distribution Channel
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Smoking Cessation and Nicotine De-Addiction Products Market

4. Smoking Cessation and Nicotine De-Addiction Products Market Macro Indicator Analysis

5. Global Smoking Cessation and Nicotine De-Addiction Products Market by Type
5.1. E-cigarettes
5.2. Drug Therapy
5.3. Nicotine Replacement Therapies

6. Global Smoking Cessation and Nicotine De-Addiction Products Market by Distribution Channel
6.1. Drug Store
6.2. Retail Pharmacies
6.3. Hospital Pharmacies
6.4. Online Pharmacies

7. Global Smoking Cessation and Nicotine De-Addiction Products Market by Region 2018-2024
7.1. North America
7.1.1. North America Smoking Cessation and Nicotine De-Addiction Products Market by Type
7.1.2. North America Smoking Cessation and Nicotine De-Addiction Products Market by Distribution Channel
7.1.3. North America Smoking Cessation and Nicotine De-Addiction Products Market by Country
7.2. Europe
7.2.1. Europe Smoking Cessation and Nicotine De-Addiction Products Market by Type
7.2.2. Europe Smoking Cessation and Nicotine De-Addiction Products Market by Distribution Channel
7.2.3. Europe Smoking Cessation and Nicotine De-Addiction Products Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Smoking Cessation and Nicotine De-Addiction Products Market by Type
7.3.2. Asia-Pacific Smoking Cessation and Nicotine De-Addiction Products Market by Distribution Channel
7.3.3. Asia-Pacific Smoking Cessation and Nicotine De-Addiction Products Market by Country
7.4. RoW
7.4.1. RoW Smoking Cessation and Nicotine De-Addiction Products Market by Type
7.4.2. RoW Smoking Cessation and Nicotine De-Addiction Products Market by Distribution Channel
7.4.3. RoW Smoking Cessation and Nicotine De-Addiction Products Market by Sub-region

8. Company profiles and competitive landscape
8.1. Competitive Landscape in the Global Smoking Cessation and Nicotine De-Addiction Products Market
8.2. Companies Profiles
8.2.1. Takeda Pharmaceutical Co., Ltd.
8.2.1.1. Overview
8.2.1.2. Company Snapshot
8.2.1.3. Financial Snapshot
8.2.1.4. Product portfolio
8.2.1.5. Recent developments
8.2.2. Pfizer, Inc.
8.2.2.1. Overview
8.2.2.2. Company Snapshot
8.2.2.3. Financial Snapshot
8.2.2.4. Product portfolio
8.2.2.5. Recent developments
8.2.3. NJOY, Inc.
8.2.3.1. Overview
8.2.3.2. Company Snapshot
8.2.3.3. Financial Snapshot
8.2.3.4. Product portfolio
8.2.3.5. Recent developments
8.2.4. Imperial Tobacco Company of India Limited.
8.2.4.1. Overview
8.2.4.2. Company Snapshot
8.2.4.3. Financial Snapshot
8.2.4.4. Product portfolio
8.2.4.5. Recent developments
8.2.5. Cipla Ltd.
8.2.5.1. Overview
8.2.5.2. Company Snapshot
8.2.5.3. Financial Snapshot
8.2.5.4. Product portfolio
8.2.5.5. Recent developments
8.2.6. Revolymer PLC
8.2.6.1. Overview
8.2.6.2. Company Snapshot
8.2.6.3. Financial Snapshot
8.2.6.4. Product portfolio
8.2.6.5. Recent developments
8.2.7. Novartis International AG
8.2.7.1. Overview
8.2.7.2. Company Snapshot
8.2.7.3. Financial Snapshot
8.2.7.4. Product portfolio
8.2.7.5. Recent developments
8.2.8. Mcneil AB
8.2.8.1. Overview
8.2.8.2. Company Snapshot
8.2.8.3. Product portfolio
8.2.8.4. Recent developments
8.2.9. Glaxo Smith Kline PLC
8.2.9.1. Overview
8.2.9.2. Company Snapshot
8.2.9.3. Financial Snapshot
8.2.9.4. Product portfolio
8.2.9.5. Recent developments

9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Takeda Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • NJOY, Inc.
  • Imperial Tobacco Company of India Limited.
  • Cipla Ltd.
  • Revolymer PLC
  • Novartis International AG
  • McNeil AB
  • GlaxoSmithKline Plc
Note: Product cover images may vary from those shown
Adroll
adroll